Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Autor: Fonseca NM; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Maurice-Dror C; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Herberts C; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Tu W; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Fan W; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Murtha AJ; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Kollmannsberger C; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Kwan EM; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.; Department of Medicine, School of Clinical Sciences; Monash University, Melbourne, VIC, Australia., Parekh K; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Schönlau E; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Bernales CQ; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Donnellan G; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Ng SWS; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Sumiyoshi T; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Vergidis J; Department of Medical Oncology, BC Cancer, Victoria, BC, Canada., Noonan K; Department of Medical Oncology, BC Cancer, Surrey, BC, Canada., Finch DL; Department of Medical Oncology, BC Cancer, Kelowna, BC, Canada., Zulfiqar M; Department of Medical Oncology, BC Cancer, Abbotsford, BC, Canada., Miller S; Department of Radiation Oncology, BC Cancer, Prince George, BC, Canada., Parimi S; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Lavoie JM; Department of Medical Oncology, BC Cancer, Victoria, BC, Canada., Hardy E; Tom McMurtry & Peter Baerg Cancer Centre, Vernon Jubilee Hospital, Vernon, BC, Canada., Soleimani M; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Nappi L; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Eigl BJ; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Kollmannsberger C; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Taavitsainen S; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland., Nykter M; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland., Tolmeijer SH; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University, Nijmegen, The Netherlands., Boerrigter E; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University, Nijmegen, The Netherlands., Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University, Nijmegen, The Netherlands., van Erp NP; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University, Nijmegen, The Netherlands., De Laere B; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.; Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, Belgium.; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden., Lindberg J; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden., Grönberg H; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden., Khalaf DJ; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada., Annala M; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. matti.annala@tuni.fi.; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland. matti.annala@tuni.fi., Chi KN; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. kchi@bccancer.bc.ca.; Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada. kchi@bccancer.bc.ca., Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. awwyatt@mail.ubc.ca.; Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada. awwyatt@mail.ubc.ca.

Publikováno v: Nature communications [Nat Commun] 2024 Feb 28; Vol. 15 (1), pp. 1828. Date of Electronic Publication: 2024 Feb 28.

HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.

Autor: Khalaf DJ; BC Cancer Vancouver, Vancouver, BC, Canada., Aragón IM; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain., Annala M; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Lozano R; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain., Taavitsainen S; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland., Lorente D; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Hospital General Universitari de Castelló, Castellon, Spain., Finch DL; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; BC Cancer Kelowna, Kelowna, BC, Canada., Romero-Laorden N; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain., Vergidis J; BC Cancer Victoria, Victoria, BC, Canada., Cendón Y; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Oja C; BC Cancer Surrey, Surrey, BC, Canada., Pacheco MI; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain., Zulfiqar M; BC Cancer Abbotsford, Abbotsford, BC, Canada., Gleave ME; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Wyatt AW; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Olmos D; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain., Chi KN; BC Cancer Vancouver, Vancouver, BC, Canada; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Castro E; Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional de Málaga, Malaga, Spain. Electronic address: elena.castro@ibima.eu.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2020 Sep; Vol. 31 (9), pp. 1186-1197. Date of Electronic Publication: 2020 Jun 20.

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.

Autor: Khalaf DJ; Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Sunderland K; Department of Biostatistics, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Eigl BJ; Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Kollmannsberger CK; Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Ivanov N; Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada., Finch DL; Department of Medical Oncology, BC Cancer Southern Interior, Kelowna, BC, Canada., Oja C; Department of Medical Oncology, BC Cancer Fraser Valley, Surrey, BC, Canada., Vergidis J; Department of Medical Oncology, BC Cancer Island Centre, Victoria, BC, Canada., Zulfiqar M; Department of Medical Oncology, BC Cancer Abbotsford Centre, Abbotsford, BC, Canada., Gleave ME; Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada., Chi KN; Department of Medical Oncology, BC Cancer Vancouver Centre, Vancouver, BC, Canada; Department of Urological Sciences, The Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada. Electronic address: kchi@bccancer.bc.ca.

Publikováno v: European urology [Eur Urol] 2019 Jun; Vol. 75 (6), pp. 940-947. Date of Electronic Publication: 2018 Dec 24.